Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

von Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., Ullrich, S. J., Fisher, G. A., Tolcher, A. W.
Veröffentlicht 2010

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

von Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C., Tran, N.
Veröffentlicht 2012

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

von Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Veröffentlicht 2013

Marked inactivation of O(6)-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

von Tolcher, A W, Gerson, S L, Denis, L, Geyer, C, Hammond, L A, Patnaik, A, Goetz, A D, Schwartz, G, Edwards, T, Reyderman, L, Statkevich, P, Cutler, D L, Rowinsky, E K
Veröffentlicht 2003

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

von Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K
Veröffentlicht 2014

PD-019 ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)

von Mazzaferro, V., Shaib, W., Rimassa, L., Harris, W., Personeni, N., El-Rayes, B., Tolcher, A., Hall, T., Wang, Y., Schwartz, B., Kazakin, J., Droz Dit Busset, M., Cotsoglou, C., Papadopoulos, K.
Veröffentlicht in Ann Oncol (2016)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

von Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Veröffentlicht 2011

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

von Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L
Veröffentlicht in Br J Cancer (2017)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin...

von Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R. K.
Veröffentlicht in Ann Oncol (2016)